Department of Physiology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.
Hypertension. 2010 Nov;56(5):934-41. doi: 10.1161/HYPERTENSIONAHA.110.160853. Epub 2010 Oct 4.
Rho-mediated inhibition of myosin light chain (MLC) phosphatase (MLCP), together with Ca(2+)-dependent MLC kinase activation, constitutes the major signaling mechanisms for vascular smooth muscle contraction. We recently unveiled the involvement of Ca(2+)-induced, phosphoinositide 3-kinase (PI3K) class IIα isoform (PI3K-C2α)-dependent Rho activation and resultant Rho kinase-dependent MLCP suppression in membrane depolarization- and receptor agonist-induced contraction. It is unknown whether Ca(2+)- and PI3K-C2α-dependent regulation of MLCP is altered in vascular smooth muscle of hypertensive animals and is involved in hypertension. Therefore, we studied the role of the Ca(2+)-PI3K-C2α-Rho-MLCP pathway in spontaneously hypertensive rats (SHRs). PI3K-C2α was readily detected in various vascular beds of Wistar-Kyoto rats and activated by high KCl. High KCl also stimulated vascular Rho activity and phosphorylation of the MLCP regulatory subunit MYPT1 at Thr(853) in a PI3K inhibitor wortmannin-sensitive manner. In mesenteric and other vessels of SHRs at the hypertensive but not the prehypertensive stage, the activity of PI3K-C2α but not class I PI3K p110α was elevated with concomitant rises of Rho activity and Thr(853)-phosphorylation of MYPT1, as compared with normotensive controls. Infusion of the Ca(2+) channel antagonist nicardipine reduced blood pressure with suppression of vascular activity of PI3K-C2α-Rho and phosphorylation of MYPT1 in hypertensive SHRs. Infusion of wortmannin lowered blood pressure with inhibition of PI3K-C2α-Rho activities and MYPT1 phosphorylation in hypertensive SHRs. These observations suggest that an increased activity of the Ca(2+)-PI3K-C2α-Rho signaling pathway with resultant augmented MLCP suppression contributes to hypertension in SHRs. The Ca(2+)- and PI3K-C2α-dependent Rho stimulation in vascular smooth muscle may be a novel, promising target for treating hypertension.
Rho 介导的肌球蛋白轻链(MLC)磷酸酶(MLCP)抑制作用,以及 Ca(2+)依赖性 MLC 激酶的激活,构成了血管平滑肌收缩的主要信号机制。我们最近揭示了 Ca(2+)诱导的、磷酸肌醇 3-激酶(PI3K)IIα 同工型(PI3K-C2α)依赖性 Rho 激活以及由此导致的 Rho 激酶依赖性 MLCP 抑制作用在膜去极化和受体激动剂诱导的收缩中的作用。尚不清楚血管平滑肌中 Ca(2+)和 PI3K-C2α 依赖性的 MLCP 调节在高血压动物中是否发生改变,以及是否与高血压有关。因此,我们研究了 Ca(2+)-PI3K-C2α-Rho-MLCP 通路在自发性高血压大鼠(SHR)中的作用。PI3K-C2α 很容易在 Wistar-Kyoto 大鼠的各种血管床中被检测到,并被高 KCl 激活。高 KCl 还以 PI3K 抑制剂wortmannin 敏感的方式刺激血管 Rho 活性和 MLCP 调节亚基 MYPT1 的 Thr(853)磷酸化。在高血压但非高血压前期的 SHR 的肠系膜和其他血管中,PI3K-C2α 的活性升高,而不是 I 类 PI3K p110α 的活性升高,同时 Rho 活性和 MYPT1 的 Thr(853)磷酸化也升高,与正常血压对照组相比。钙通道拮抗剂尼卡地平的输注降低了血压,同时抑制了高血压 SHR 中血管 PI3K-C2α-Rho 的活性和 MYPT1 的磷酸化。wortmannin 的输注降低了高血压 SHR 的血压,同时抑制了 PI3K-C2α-Rho 的活性和 MYPT1 的磷酸化。这些观察结果表明,Ca(2+)-PI3K-C2α-Rho 信号通路活性的增加导致 MLCP 抑制作用增强,这有助于 SHR 的高血压。血管平滑肌中 Ca(2+)和 PI3K-C2α 依赖性的 Rho 刺激可能是治疗高血压的一个新的、有前途的靶点。